Brief: Sorrento Releases Positive Results From A Phase 1B Study In China In Covid-19 Patients And Is Ready For Pivotal Phase 3 Trials With Ovydso™ (Sti-1558), An Oral Mpro Inhibitor As A Standalone Treatment For Covid-19 Without The Need For Ritonavir Boosting

Sorrento Therapeutics

09/01/2023 14:03

Sorrento Therapeutics Inc  SRNE.O :
    * SORRENTO RELEASES POSITIVE RESULTS FROM A PHASE 1B STUDY
IN
CHINA IN COVID-19 PATIENTS AND IS READY FOR PIVOTAL PHASE 3
TRIALS WITH OVYDSO™ (STI-1558), AN ORAL MPRO INHIBITOR AS A
STANDALONE TREATMENT FOR COVID-19 WITHOUT THE NEED FOR RITONAVIR
BOOSTING
    * SORRENTO RELEASES POSITIVE RESULTS FROM A PHASE 1B STUDY
IN
CHINA IN COVID-19 PATIENTS AND IS READY FOR PIVOTAL PHASE 3
TRIALS WITH OVYDSO™ (STI-1558), AN ORAL MPRO INHIBITOR AS A
STANDALONE TREATMENT FOR COVID-19 WITHOUT THE NEED FOR RITONAVIR
BOOSTING
    * SORRENTO THERAPEUTICS INC - STI-1558 WAS WELL-TOLERATED AT
ALL
DOSES TESTED
    * SORRENTO THERAPEUTICS - PHASE 3 PROTOCOL IN 1200 COVID-19
PATIENTS HAS BEEN SUBMITTED TO NATIONAL MEDICAL PRODUCTS
ADMINISTRATION OF CHINA
    * SORRENTO THERAPEUTICS - PHASE 3 TRIAL WILL BE COMMENCED
SOON IN
CHINA TOGETHER WITH A PLANNED U.S. PHASE 2 TRIAL AND A PLANNED
MEXICO PHASE 2/3 TRIAL

Source text for Eikon:  ID:nGNXcZfzM 
Further company coverage:  SRNE.O